Skip to main content
SpringerLink
Log in

Sentinel lymph node mapping and selective lymphadenectomy: The standard of care for melanoma

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Selective sentinel lymphadenectomy (SSL) should be considered a standard of care approach for staging patients with primary invasive melanoma 1 mm or greater. It is essential that multidisciplinary teams should master the techniques of preoperative lymphoscintigraphy, intraoperative lymphatic mapping, and pathologic evaluation of the sentinel lymph nodes (SLNs). An SLN may be blue, hot, or any lymph node (LN) greater than 10% of the in-vivo count of the hottest LN. An enlarged or indurated LN should be removed because it may contain metastatic cancer cells that block blue dye or radiotracer entry. Frozen sections are not recommended. Surgeons who use isosulfan blue dye should be cognizant of treatment for a potentially fatal reaction. Prophylactic LN dissection should not be performed if a SSL can be performed as a staging procedure. A complete LN dissection is performed if the SLN is positive. It is important to follow the clinical outcome of patients undergoing SSL, thus its role can be further defined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Bedrosian I, Gershenwald JE: Surgical clinical trials in melanoma. Surg Clin North Am 2003, 83:385–403. This paper summarizes the results of clinical trials in melanoma surgery.

    Article  PubMed  Google Scholar 

  2. Morton DL, Wen DR, Wong JH, et al.: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127:392–399.

    PubMed  CAS  Google Scholar 

  3. Leong SP: Selective sentinel lymphadenectomy for malignant melanoma. Surg Clin North Am 2003, 83:157–185. This paper summarizes the concept, techniques, and clinical outcome of patients with melanoma undergoing SSL. This paper is critical for physicians to become familiar with SSL for melanoma.

    Article  PubMed  Google Scholar 

  4. Morton DL, Thompson JF, Essner R, et al.: Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg 1999, 230:453–465.

    Article  PubMed  CAS  Google Scholar 

  5. Leong S: Selective sentinel lymph node mapping and dissection for malignant melanoma. In Atlas of Selective Sentinel Lymphadenectomy for Melanoma, Breast Cancer and Colon Cancer. Edited by Leong SP. Boston: Kluwer Academic Publishers; 2002:39–64.

    Chapter  Google Scholar 

  6. Morita ET: Lymphoscintigraphy in the detection of sentinel lymph nodes. In Atlas of Selective Sentinel Lymphadenectomy for Melanoma, Breast Cancer and Colon Cancer. Edited by Leong S. Boston: Kluwer Academic Publishers; 2002:9–38.

    Chapter  Google Scholar 

  7. Leong SP, Donegan E, Heffernon W, et al.: Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol 2000, 7:361–366. This paper describing adverse reactions is the first paper documenting the side effects of blue dye in the SLN era.

    Article  PubMed  CAS  Google Scholar 

  8. Leong SP, Steinmetz I, Habib F, et al.: Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 1997, 132:666–672.

    PubMed  CAS  Google Scholar 

  9. Reintgen D, Balch CM, Kirkwood J, Ross M: Recent advances in the care of the patient with malignant melanoma. Ann Surg 1997, 225:1–14.

    Article  PubMed  CAS  Google Scholar 

  10. Gershenwald JE, Tseng CH, Thompson W, et al.: Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 1998, 124:203–210.

    PubMed  CAS  Google Scholar 

  11. Albertini JJ, Cruse CW, Rapaport D, et al.: Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996, 223:217–224.

    Article  PubMed  CAS  Google Scholar 

  12. McMasters KM, Reintgen DS, Ross MI, et al.: Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol 2001, 8:192–197. This paper establishes the rule for harvesting SLNs with different radioactive counts based on a multicenter database.

    Article  PubMed  CAS  Google Scholar 

  13. Treseler PA, Tauchi PS: Pathologic analysis of the sentinel lymph node. Surg Clin North Am 2000, 80:1695–1719.

    Article  PubMed  CAS  Google Scholar 

  14. Reintgen DS, Albertini J, Berman C, et al.: Accurate nodal staging of malignant melanoma. Cancer Control J Moffitt Cancer Center 1995, 2:405–414.

    Google Scholar 

  15. Robert M, Wen D, Cochran A: Pathological evaluation of the regional lymph nodes in malignant melanoma. Semin Diagn Pathol 1993, 10:102–115.

    PubMed  CAS  Google Scholar 

  16. Wang X, Heller R, VanVoorheis N, et al.: Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994, 220:768–774.

    Article  PubMed  CAS  Google Scholar 

  17. Tanis PJ, Boom RP, Koops HS, et al.: Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol 2001, 8:222–226.

    Article  PubMed  CAS  Google Scholar 

  18. Rosen PP, Lesser ML, Kinne DW, Beattie EJ: Discontinuous or “skip” metastases in breast carcinoma. Ann Surg 1983, 197:276–283.

    Article  PubMed  CAS  Google Scholar 

  19. Bonenkamp JJ, Logan DR, Suemnig AA, Thompson JF: The cost of sentinel node biopsy (SNB) for melanoma. Melanoma Res 2001, 11:S107.

    Google Scholar 

  20. Hettiaratchy SP, Kange N, O’Toole G, et al.: Sentinel lymph node biopsy in malignant melanoma: a series of 100 consecutive patients. Br J Plast Surg 2000, 53:559–662.

    Article  PubMed  CAS  Google Scholar 

  21. Albo D, Wayne J, Hunt K, et al.: Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg 2001, 130:439–442.

    Google Scholar 

  22. Montgomery LL, Thorne AC, Van Zee KJ, et al.: Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg 2002, 95:385–388.

    Article  PubMed  Google Scholar 

  23. Reintgen DS, Cruse CW, Wells K, et al.: The orderly progression of melanoma nodal metastases. Ann Surg 1994, 220:759–767.

    Article  PubMed  CAS  Google Scholar 

  24. Thompson JF, McCarthy WH, Bosch CM, et al.: Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995, 5:255–260.

    PubMed  CAS  Google Scholar 

  25. Krag DN, Meijer SJ, Weaver DL, et al.: Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995, 130:654–658.

    PubMed  CAS  Google Scholar 

  26. Ross MI, Reintgen DS, Balch CM: Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993, 9:219–223.

    PubMed  CAS  Google Scholar 

  27. Reintgen DS: Changing standards of surgical care for the melanoma patient. Ann Surg Oncol 1996, 3:327–328.

    Article  PubMed  CAS  Google Scholar 

  28. Coit D, Wallack M, Balch C: Society of surgical oncology practice guidelines: melanoma surgical practice guidelines. Oncology 1997, 11:1317–1323.

    PubMed  CAS  Google Scholar 

  29. Emilia JC, Lawrence W: Sentinel lymph node biopsy in malignant melanoma: the standard of care? J Surg Oncol 1997, 65:153–154.

    Article  PubMed  CAS  Google Scholar 

  30. Houghton A, Coit D, Bloomer W, et al.: NCCN melanoma practice guidelines. National Comprehensive Cancer Network. Oncology 1998, 12:153–177.

    PubMed  CAS  Google Scholar 

  31. Hauschild A, Rosien F, Lischner S: Surgical standards in the primary care of melanoma patients. Onkologie 2003, 26:218–222.

    Article  PubMed  CAS  Google Scholar 

  32. Balch CM, Buzaid AC, Atkins MB, et al.: A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000, 88:1484–1491.

    Article  PubMed  CAS  Google Scholar 

  33. Tanis PJ, Nieweg OE, Hart AA, Kroon BB: The illusion of the learning phase for lymphatic mapping. Ann Surg Oncol 2002, 9:142–147.

    Article  PubMed  CAS  Google Scholar 

  34. Brobeil A, Cruse CW, Messina JL, et al.: Cost analysis of sentinel lymph node biopsy as an alternative to elective lymph node dissection in patients with malignant melanoma. Surg Oncol Clin N Am 1999, 8:435–445.

    PubMed  CAS  Google Scholar 

  35. Clary BM, Mann B, Brady MS, et al.: Early recurrence after lymphatic mapping and sentinel node biopsy in patients with primary extremity melanoma: a comparison with elective lymph node dissection. Ann Surg Oncol 2001, 8:328–337. This paper summarizes the clinical outcome of patients with extremity melanoma undergoing SSL.

    Article  PubMed  CAS  Google Scholar 

  36. Cherpelis BS, Haddad F, Messina J, et al.: Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol 2001, 44:762–766. This paper summarizes the clinical outcome of patients with melanoma undergoing SSL in relationship to high-risk factors.

    Article  PubMed  CAS  Google Scholar 

  37. Essner R, Conforti A, Kelley MC, et al.: Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 1999, 6:442–449.

    Article  PubMed  CAS  Google Scholar 

  38. Gadd MA, Cosimi AB, Yu J, et al.: Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg 1999, 134:381–387.

    Article  PubMed  CAS  Google Scholar 

  39. Gershenwald JE, Thompson W, Mansfield PF, et al.: Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999, 17:976–983.

    PubMed  CAS  Google Scholar 

  40. Statius Muller MG, van Leeuwen PA, de Lange-De Klerk ES, et al.: The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer 2001, 91:2401–2408. This paper summarizes the relationship of SLN status and clinical outcome of patients with melanoma undergoing SSL.

    Article  Google Scholar 

  41. Starz H, Balda BR, Kramer KU, et al.: A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 2001, 91:2110–2121. This paper proposes a novel approach to define micrometastasis in melanoma SLNs.

    Article  PubMed  CAS  Google Scholar 

  42. Starz H, De Donno A, Balda BR: The Augsburg experience: histological aspects and patient outcomes. Ann Surg Oncol 2001, 8:48S-51S. This paper proposes a novel approach to define micrometastasis in melanoma SLNs.

    PubMed  CAS  Google Scholar 

  43. Morton DL, Hoon DS, Cochran AJ, et al.: Lymphatic mapping and sentinel lymphadenectomy for earlystage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003, 238:538–549. This paper defines the clinical significance of tumor burden in the SLNs at a molecular level.

    PubMed  Google Scholar 

  44. Bostick P, Morton DL, Turner RR, et al.: Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999, 17:3238–3244.

    PubMed  CAS  Google Scholar 

  45. Davis EG, Chao C, McMasters KM: Polymerase chain reaction in the staging of solid tumors. Cancer J 2002, 8:135–143.

    Article  PubMed  Google Scholar 

  46. McMasters K, Reintgen D, Ross M, et al.: Sunbelt melanoma trials: sensitivity and specificity of reverse transcriptase polymerase chain reaction (RT-PCR) markers for sentinel lymph nodes (SLN). In Proceedings of the American Society of Clinical Oncology. Atlanta: American Society of Clinical Oncology; 1999:537a.

    Google Scholar 

  47. Coldiron B: No evidence to support delay in excision of malignant melanoma. Arch Dermatol 2000, 136:1269–1270.

    Article  PubMed  CAS  Google Scholar 

  48. Leong S: No evidence to support delay in excision of malignant melanoma. Arch Dermatol 2000, 136:1269–1270.

    Article  PubMed  Google Scholar 

  49. Leong S, Thelmo MC, Kim RP, et al.: Delayed harvesting of sentinel lymph nodes after previous wide local excision of extremity melanoma. Ann Surg Oncol 2003, 10:196–200.

    Article  PubMed  Google Scholar 

  50. Kelley SW, Cockerell CJ: Sentinel lymph node biopsy as an adjunct to management of histologically difficult to diagnose melanocytic lesions: a proposal. J Am Acad Dermatol 2000, 42:527–530.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of California, San Francisco/ Mount Zion Medical Center and UCSF Comprehensive Cancer Center, 1600 Divisadero Street, Room C333, 94143, San Francisco, CA, USA

    Stanley P. L. Leong MD, FACS

Authors
  1. Stanley P. L. Leong MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leong, S.P.L. Sentinel lymph node mapping and selective lymphadenectomy: The standard of care for melanoma. Curr. Treat. Options in Oncol. 5, 185–194 (2004). https://doi.org/10.1007/s11864-004-0010-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-004-0010-x

Keywords

Search

Navigation